The global market for neurodegenerative drugs is projected to grow from $27.2bn in 2015 to $45bn by 2022, according to a report by GBI Research.

Titled ‘Global Neurodegenerative Drugs Market to 2022’, the report forecasts the neurodegenerative disorders market to grow at a compound annual growth rate of 7.42%.

"Late-stage products currently under development, including ocrelizumab, ozanimod, solanezumab, ITI-007 and RG-7412, are expected to be commercially successful."

The majority of the growth is expected to occur between 2018 and 2022 with the approval of a number of pipeline products. A total of 1,494 products are currently in active development in the neurodegenerative disorders space, most of which are novel drugs, while the remaining are either generics or repositioned products.

Late-stage products currently under development, including ocrelizumab, ozanimod, solanezumab, ITI-007 and RG-7412, are expected to be commercially successful.

Leading players such as Biogen, Novartis and Sanofi are expected to maintain their position in the market despite impending patent expiries of Biogen’s Tysabri and Novartis’ Gilenya, which are expected to affect sales, according to GBI Research analyst Qaisrah Khalid.

Revenues from Teva’s Copaxone (glatiramer acetate) are expected to decrease from $4bn in 2015 to $2.5bn by 2022, following patent expiry in 2014. Approval of ocrelizumab, however, is expected to boost Roche’s revenues and establishing it as the leading player in the market, adds Khalid.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.